A Glutathione Activatable Photosensitizer for Combined Photodynamic and Gas Therapy under Red Light Irradiation

Although photodynamic therapy (PDT) is a promising approach for cancer therapy, most existing photosensitizers lack selectivity for tumor cells and the overexpressed glutathione (GSH) in tumor cells reduces the PDT efficiency. Therefore, designing photosensitizers that can be selectively activated w...

Full description

Saved in:
Bibliographic Details
Published in:Advanced healthcare materials 2022-02, Vol.11 (4), p.e2102017-n/a
Main Authors: Wang, Ran, Xia, Xiang, Yang, Yanjun, Rong, Xiang, Liu, Ting, Su, Zehou, Zeng, Xiaolong, Du, Jianjun, Fan, Jiangli, Sun, Wen, Peng, Xiaojun
Format: Article
Language:English
Subjects:
activatable photosensitizer
Anticancer properties
Cages
Cancer
Cancer therapies
Cell Line, Tumor
gas therapy
Glutathione
Light irradiation
mitochondria‐targeting
Photochemotherapy - methods
Photodynamic therapy
Photosensitizing Agents - pharmacology
Photosensitizing Agents - therapeutic use
Radiation
red‐light therapy
Selectivity
Singlet Oxygen
Tumor cells
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although photodynamic therapy (PDT) is a promising approach for cancer therapy, most existing photosensitizers lack selectivity for tumor cells and the overexpressed glutathione (GSH) in tumor cells reduces the PDT efficiency. Therefore, designing photosensitizers that can be selectively activated within tumor cells and combine PDT with other therapeutic modalities represents a route for precise and efficient anticancer treatment. Herein, an organic activatable photosensitizer, CyI‐DNBS, bearing 2,4‐dinitrobenzenesulfonate (DNBS) as the cage group is reported. CyI‐DNBS can be uptaken by cancer cells after which the cage group is selectively removed by the intracellular GSH, resulting in the generation of SO2 for gas therapy. The reaction also releases the activated photosensitizer, CyI‐OH, that can produce singlet oxygen (1O2) under red light irradiation. Therefore, CyI‐DNBS targets cancer cells for both photodynamic and SO2 gas therapy treatments. The activatable photosensitizer provides a new approach for PDT and SO2 gas synergistic therapy and demonstrates excellent anticancer effect in vivo. A photosensitizer CyI‐DNBS is reported which releases SO2 via glutathione activation for gas therapy. Meanwhile, the activated photosensitizer is capable of producing cytotoxic 1O2 for photodynamic therapy (PDT) under red light irradiation. CyI‐DNBS has demonstrated highly effective therapeutic effects and can significantly inhibit the tumor growth in vivo, providing a new platform for combined PDT and gas therapy.
ISSN:2192-2640
2192-2659
DOI:10.1002/adhm.202102017